Science & Technology
Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44HL174192-01A1
Award Ceiling
$2.4M
Award Floor
$2.4M
Close Date
Jun 30, 2026
107 days leftTotal Funding
$2.4M
Expected Awards
1
Posted Date
Sep 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R44HL174192-01A1
Description
SBIR Phase Phase II award: "Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist" awarded to SHIFA BIOMEDICAL CORPORATION in MALVERN, Pennsylvania. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,418,072. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.